Intravitreal Ranibizumab for the Treatment of Choroidal Neovascularization in Best’s Vitelliform Macular Dystrophy

To evaluate the results of intravitreal ranibizumab injection in a case with choroidal neovascularization (CNV) in Best’s vitelliform macular dystrophy with different imaging modalities. A 20-year-old male with the complaint of reduced vision in the right eye underwent complete ophthalmological examination including fluorescein angiography (FA), fundus autofluorescence (FAF) imaging. Macular scans were obtained with spectral optical coherence tomography (OCT). Best corrected visual acuity was counting fingers at 2 meters in the right eye. Fluorescein angiography and OCT confirmed the diagnosis of  CNV associated with Best’s vitelliform macular dystrophy. After 3 monthly injections of intravitreal ranibizumab, CNV regressed and macular edema disappeared. Visual acuity improved to 10 / 10. His condition remained stable for 3 years after treatment. We concluded that the intrav itreal ranibizumab may be a new approach for the therapy of CNV in Best’s vitelliform macular dystrophy.  However, a long-term follow-up is warranted. Different imaging modalities help us to understand the different aspects of macular involvement in this disease complicated with CNV. doi:10.4021/jmc619w